Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer at Agenus and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center, will participate in a webcast hosted by Dr. Matt Phipps, biotechnology analyst at William Blair on Friday, November 12, 2021 at 12:00 p.m. ET.
Dr. Steven O’Day and Dr. Manuel Hidalgo will review the updated Phase 1 clinical trial results for AGEN1181 (Fc-enhanced anti-CTLA-4) alone and in combination with balstilimab (anti-PD-1), which will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting on November 12th, 2021. They will also discuss the significance of these data and how they may inform the path forward for continued development.
Registration for the webinar can be done in advance at https://williamblair.zoom.us/webinar/register/WN_WzxgjO1MRw6dKIWm3nAg-w
A replay will be available after the call for 30 days on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its affiliate MiNK Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of therapeutic candidates AGEN 1181 and balstilimab, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of the therapeutic candidates, both alone and in combination with each other and/or other agents; future clinical and regulatory development plans for AGEN1181 alone and in combination with other agents, including balstilimab; our ability to obtain regulatory approval for AGEN1181, alone and in combination with other agents, including balstilimab, including the timing (including the possibility of accelerated review) and scope of any such regulatory approval; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Divya Vasudevan, PhD
Agenus Media Relations